Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 43.37 based on a 26x P/E ratio for 2025 [3][5]. Core Insights - The company is a leading player in the traditional Chinese medicine (TCM) chain service sector, with a strong AI strategy and significant growth potential. The revenue is projected to grow at a CAGR of 26.8% from 2018 to 2024, with 2024 revenue expected to reach HKD 30.2 billion, representing a 30.1% year-on-year increase [9][38]. - The TCM market in China is expected to grow significantly, with the market size projected to reach CNY 2.97 trillion by 2030, driven by factors such as an aging population and increasing public awareness of TCM [38][42]. Summary by Sections Company Overview - Established in 2010, the company has expanded its offline presence in major cities and developed an online platform, becoming a comprehensive TCM healthcare service provider [14][9]. - The company has achieved a stable business model integrating online and offline services, focusing on patient acquisition, consultation, diagnosis, and follow-up care [17][31]. Financial Performance - Revenue is forecasted to grow from HKD 2.32 billion in 2023 to HKD 5.72 billion in 2027, with a projected net profit of HKD 538.88 million in 2027 [3][4]. - The company has shown a consistent increase in adjusted net profit, with a forecasted growth of 31.4% in 2024 [27][36]. Market Potential - The TCM service market is characterized by high growth and low concentration, with the top five players holding only a 1.5% market share. The company currently holds a 0.2% market share, indicating significant room for growth [56][38]. - The demand for TCM services is driven by demographic changes, lifestyle diseases, and increasing cultural acceptance of TCM practices [42][38]. AI and Innovation - The company has been investing in AI since 2019, aiming to enhance TCM services and facilitate the internationalization of TCM products [9][3]. - Collaborations with institutions like West China Hospital and Baidu are underway to develop AI-assisted TCM solutions, which could revolutionize the delivery of TCM services [9][3]. Competitive Landscape - The TCM industry is fragmented, with many small players, creating opportunities for consolidation and growth for established companies like the one in the report [56][53]. - The regulatory environment is becoming increasingly favorable for private TCM institutions, promoting high-quality development in the sector [46][47].

| 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | 港元） | （港元） | （港元） | （万港元） | | 00700 | 腾讯控股 | 97.50 | 50084.93 | 516.500 | 511.500 | 2853315.68 | | 01299 | 友邦保险 | 300.00 | 20382.49 | 69.000 | 67.150 | 1206539.55 | | 00670 | 中国东方航 空股份 | 220.00 | 648.42 | 2.970 | 2.920 | 49816.45 | | 01519 | 极兔速递-W | 92.00 | 626.52 | 6.870 | 6.730 | 25362.34 | | 09987 | 百胜中国 | 1.39 | 467.34 | 339.400 | 335.200 | 70033.89 | | 01907 | 中国旭阳集 团 | 165.00 | 412.92 | 2.5 ...

Group 1 - The Hong Kong stock market for innovative drugs has seen significant gains, with notable increases in shares of companies such as CSPC Pharmaceutical Group rising over 13%, Lepu Biopharma increasing by 9%, and King’s Ray Biotechnology up over 5% [1] - Various Hong Kong innovative drug ETFs have also performed well, with several funds, including GF Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, rising over 2% [1][2] - The approval of CSPC's adenosylcobalamin capsules by the National Medical Products Administration of China is expected to enhance the company's product line in the blood and nervous system treatment areas [4] Group 2 - Lepu Biopharma announced that its candidate drug MRG003, an innovative antibody-drug conjugate for treating recurrent or metastatic nasopharyngeal carcinoma, will present key clinical research results at the 2025 American Society of Clinical Oncology annual meeting [4] - King’s Ray Biotechnology reported that its affiliate Legend Biotech submitted a 6-K form to the SEC, revealing long-term results from the CARTITUDE-1 study, indicating that one-third of patients did not experience disease progression for five years or more after a single CARVYKTI infusion [5] - According to research reports, the pharmaceutical sector is expected to experience a turning point this year, with strong growth in profitability anticipated over the next two years, driven by favorable policies and macroeconomic recovery [5][6]

证券时报·数据宝统计显示，6月5日有29家香港上市公司进行了股份回购，合计回购1829.91万股，回购 金额7.89亿港元。 腾讯控股回购数量97.50万股，回购金额5.01亿港元，回购最高价为517.500港元，最低价为509.500港 元，年内累计回购金额280.32亿港元；友邦保险回购数量350.00万股，回购金额2.34亿港元，回购最高 价为67.600港元，最低价为66.350港元，年内累计回购金额118.62亿港元；石四药集团回购数量540.00万 股，回购金额1509.58万港元，回购最高价为2.800港元，最低价为2.770港元，年内累计回购金额6610.49 万港元。 以金额进行统计，6月5日回购金额最多的是腾讯控股，回购金额为5.01亿港元；其次是友邦保险，回购 金额为2.34亿港元；回购金额居前的还有石四药集团、和铂医药-B等。回购数量上看，6月5日回购股数 最多的是石四药集团，当日回购量为540.00万股；其次是友邦保险、中国旭阳集团等，回购数量分别为 350.00万股、180.00万股。 值得关注的是，本次回购5.01亿港元的腾讯控股，年内则进行多次回购，合计回购金额为280.32亿 ...

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [31]. Core Insights - The MSCI China Healthcare Index has increased by 27.6% since the beginning of 2025, outperforming the MSCI China Index by 14.5% [2]. - The international competitiveness of Chinese innovative drugs is being demonstrated through significant overseas licensing deals, reflecting a strong market presence [2]. - The report anticipates a valuation recovery in the pharmaceutical industry by 2025, driven by factors such as overseas licensing transactions, optimization of domestic procurement policies, and the implementation of new medical insurance categories [5]. Summary by Sections 1. **Industry Research - Medical Insurance Negotiations** - Continued support for innovation and recovery in overseas R&D demand [5]. 2. **Industry Research - Medical Equipment** - Expected recovery in bidding for medical devices and fruitful outcomes from innovative drug overseas transactions [5]. 3. **Industry Research - Medical Insurance Directory** - The results of adjustments to the medical insurance directory are expected to continuously support innovation [5]. 4. **Industry Research - Ongoing Policy Efforts** - Positive outlook for valuation rebound due to sustained policy support [5]. 5. **Industry Research - New Medical Insurance Categories** - The introduction of new medical insurance categories is expected to open up domestic payment space for innovative drugs [5]. 6. **Industry Research - Valuation Recovery** - The industry is poised for a valuation recovery, with several companies recommended for purchase [5]. 7. **Industry Research - Drug Pricing Policies** - Drug pricing policies are expected to be optimized, with accelerated commercialization of medical AI [5]. 8. **Industry Research - Anticipated Drug Procurement Policy Optimization** - Expectations for the implementation of an "innovative drug directory" [5]. 9. **Industry Research - 2024 Performance Review** - Innovative drugs are expected to dominate the market [5].

Core Insights - On June 3, 40 Hong Kong-listed companies conducted share buybacks, totaling 27.7357 million shares and an aggregate amount of HKD 1.079 billion [1][2] - Tencent Holdings led the buybacks with 994,000 shares repurchased for HKD 500 million, bringing its total buyback amount for the year to HKD 27.031 billion [1][2] - AIA Group followed with a buyback of 6 million shares for HKD 403 million, and Kuaishou-W repurchased 2 million shares for HKD 102 million [1][2] Buyback Details - Tencent Holdings: - Shares repurchased: 994,000 - Buyback amount: HKD 500 million - Highest price: HKD 505.000 - Lowest price: HKD 501.000 - Year-to-date total buyback: HKD 27.031 billion [2] - AIA Group: - Shares repurchased: 6 million - Buyback amount: HKD 403 million - Highest price: HKD 67.650 - Lowest price: HKD 66.550 - Year-to-date total buyback: HKD 11.412 billion [2] - Kuaishou-W: - Shares repurchased: 2 million - Buyback amount: HKD 102 million - Highest price: HKD 51.350 - Lowest price: HKD 50.950 - Year-to-date total buyback: HKD 1.911 billion [2] Other Notable Buybacks - Other companies with significant buybacks include: - Hengan International: 600,000 shares for HKD 13.13 million - China Eastern Airlines: 200,000 shares for HKD 592,760 [2] - The total buyback activity reflects a trend among companies to return capital to shareholders amid market conditions [1][2]

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical industry, specifically recommending an "Accumulate" rating for both the pharmaceutical manufacturing and pharmaceutical services sectors [1][2]. Core Insights - Continuous attention is suggested on innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug industry is experiencing a high demand for assets, with multinational corporations showing greater interest than concerns over geopolitical risks [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Monthly Portfolio Performance - The report highlights a monthly portfolio for June 2025, including companies such as Jiangsu Heng Rui Medicine, Huadong Medicine, and Sichuan Kelun Pharmaceutical, among others [5][36]. - In May 2025, the portfolio achieved an average increase of 7.7%, outperforming the overall pharmaceutical index, which rose by 4.5% [11][37]. Market Performance - In May 2025, the pharmaceutical sector ranked first in performance, with notable sub-sectors like chemical raw materials (+10.5%) and chemical preparations (+9.6%) showing strong growth [20][37]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. International Market Comparison - The Hong Kong pharmaceutical sector outperformed the market with a rise of 7.8%, while the U.S. pharmaceutical sector underperformed, declining by 5.7% [38]. - The report identifies top-performing stocks in both markets, with significant gains in the Hong Kong sector and notable declines in the U.S. sector [38].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, specifically for pharmaceutical manufacturing and pharmaceutical services [1][2]. Core Insights - Continuous attention is recommended for innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug sector is experiencing a significant demand from multinational corporations (MNCs), which is reflected in the increasing number of overseas business development (BD) transactions [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Investment Highlights - The report highlights a portfolio of A-Shares including Jiangsu Heng Rui Medicine, Huadong Medicine, Sichuan Kelun Pharmaceutical, and others, indicating a focus on companies with strong growth potential [2][5]. - The report notes that the pharmaceutical sector's premium level relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. Performance Analysis - In May 2025, the pharmaceutical sector's performance was ranked first, with individual stock gains led by Staidson Beijing BioPharmaceuticals (+145.4%) and Sunshine Guojian Pharmaceutical (+99.4%) [15][37]. - The report also details the performance of the Hong Kong and U.S. pharmaceutical sectors, noting that the Hong Kong stock pharmaceutical sector outperformed the market while the U.S. sector underperformed [38]. Market Trends - The report emphasizes the upward trend in the innovative drug market, with traditional pharmaceutical companies emerging from centralized procurement challenges and entering a phase of profitability [36]. - The report indicates that the biopharmaceutical sector's sub-sectors, such as chemical raw materials and biological products, have shown strong performance, with increases of 10.5% and 7.3% respectively [20][37].

Summary of Key Points Core Viewpoint - A total of 36 companies conducted share buybacks on June 2, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.013 million shares for a total of 501 million CNY, with a year-to-date cumulative buyback of 10.797 million shares, representing 0.118% of its total share capital [1][2] - AIA Group (01299) repurchased 5.448 million shares for 354 million CNY, with a cumulative buyback of 29.266 million shares, accounting for 0.274% of its total share capital [2] - Kuaishou-W (01024) repurchased 6 million shares for 312 million CNY, with a cumulative buyback of 12.3 million shares, representing 2.826% of its total share capital [2] Group 2: Other Notable Buybacks - Times Electric (03898) repurchased 320,700 shares for 10.528 million CNY, with a cumulative buyback of 53.301 million shares, accounting for 9.823% of its total share capital [2] - Stone Four Pharmaceutical Group (02005) repurchased 7.55 million shares for approximately 20.984 million CNY, with a cumulative buyback of 7.55 million shares, representing 0.263% of its total share capital [2] - Modern Dental Group (03600) repurchased 100,000 shares for 4.181 million CNY, with a cumulative buyback of 200,000 shares, accounting for 0.021% of its total share capital [3] Group 3: Additional Companies - China Eastern Airlines (00670) repurchased 2 million shares for 596,650 CNY, with a cumulative buyback of 66.088 million shares, representing 1.277% of its total share capital [2] - Mengniu Dairy (02319) repurchased 300,000 shares for 5.225 million CNY, with a cumulative buyback of 24.596 million shares, accounting for 0.625% of its total share capital [2] - Huazheng Medical (01931) repurchased 20,000 shares for 4.260 million CNY, with a cumulative buyback of 1.824 million shares, representing 0.135% of its total share capital [3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes that the ASCO conference has catalyzed enthusiasm for innovative drug investments, with a notable increase in the number of presentations by Chinese experts [3][12] - It is believed that innovative drugs will remain the main focus of pharmaceutical investments in the medium to long term, driven by China's transition from quantity to quality and innovation in drug development, alongside increasing policy support [3][12] - Short-term factors such as US-China tariff disputes and geopolitical tensions may affect overall risk appetite, suggesting a focus on companies that can commercialize large-scale innovative drugs and those in the CXO and life sciences upstream sectors [3][12] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was 2.21%, outperforming the CSI 300 by 3.30%, ranking second among 31 primary sub-industry indices [10] - The chemical pharmaceuticals sub-sector led with a weekly return of 3.83% [10][27] - Over the past month, the sector's return was 6.42%, again ranking second among sub-industry indices [10][17] Industry Dynamics - The report highlights the importance of the ASCO conference held from May 30 to June 3, 2025, in Chicago, which has further stimulated investment interest in innovative drugs [11][12] - The report suggests focusing on the CXO and life sciences upstream sectors, as well as traditional pharmaceutical companies transitioning from generics to innovative drugs [13][14] Recommendations - Companies to watch in the innovative drug chain include Tigermed, WuXi AppTec, and others in the CRO/CDMO space [13] - For the domestic recovery line, companies like Aier Eye Hospital and Tongrentang are recommended [13] - In the self-sufficiency line, high-end medical devices and research instruments from companies like Mindray and Hualan Biological Engineering are highlighted [14] Company-Specific Insights - The report identifies specific companies with strong growth potential, such as Yaoshi Bang, which is expected to achieve a CAGR of approximately 145% in net profit from 2024 to 2027 [15] - Kangchen Pharmaceutical has maintained a net profit growth rate of over 14% for the past three years, with a projected PE of about 8 times in 2025 [15] - Guoyuyuan is expected to see operational improvements in 2025, marking a potential turning point for the company [15][16]